Mylan and Novo Nordisk Resolve Ozempic Patent Dispute, Withdraw Legal Challenge

Mylan Pharmaceuticals and Novo Nordisk have announced a resolution to their patent dispute concerning Ozempic, a highly-reputed drug used for diabetes and weight-loss management. Both companies have requested that the Patent Trial and Appeal Board terminate Mylan’s petition for a patent review, signaling an agreement between the two parties on the patent’s validity. The conflict had centered around Novo Nordisk’s ownership of the Ozempic patent, which Mylan had challenged. Legal professionals following this case can find further details in the article on Law360.